New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
CA 2374215 C · Owner: Hertogs, Kurt · Inventors: Larder, Brendan; Pauwels, Rudi Wilfried Jan; Hertogs, Kurt
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides novel mutations mutation combinations or mutational , profiles of HIV-1 reverse transcriptase and/or protease genes correlated with phenotypic resistance to HIV drugs. More particularly the present invention , relates to the use of genotypic characterization of a target population of HIV and the subsequent correlation of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention also relates to methods of utilizing the mutational profiles of the invention in databases drug development, <i>i.e.</i>, drug , design and drug modification, therapy and treatment design clinical , management and …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 25, 2000 and granted May 24, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended May 25, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 25, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.